6,425 Shares in Illumina, Inc. $ILMN Bought by Diversify Advisory Services LLC

Diversify Advisory Services LLC purchased a new stake in Illumina, Inc. (NASDAQ:ILMN) during the 2nd quarter, Holdings Channel reports. The institutional investor purchased 6,425 shares of the life sciences company’s stock, valued at approximately $1,217,000.

A number of other large investors have also recently added to or reduced their stakes in ILMN. BlackRock Inc. bought a new stake in shares of Illumina in the 2nd quarter worth about $3,374,423,000. WCM Investment Management LLC lifted its position in shares of Illumina by 45.5% during the first quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company’s stock worth $715,579,000 after purchasing an additional 1,851,848 shares during the last quarter. Bank of New York Mellon Corp acquired a new position in Illumina in the second quarter worth about $293,846,000. Invesco Ltd. increased its holdings in Illumina by 97.0% in the fourth quarter. Invesco Ltd. now owns 2,747,986 shares of the life sciences company’s stock valued at $360,426,000 after buying an additional 1,352,731 shares during the last quarter. Finally, AQR Capital Management LLC increased its holdings in Illumina by 30.3% in the fourth quarter. AQR Capital Management LLC now owns 4,426,126 shares of the life sciences company’s stock valued at $580,531,000 after buying an additional 1,028,099 shares during the last quarter. 89.42% of the stock is currently owned by institutional investors.

Insider Activity

In other Illumina news, CAO Scott D. Ericksen sold 500 shares of the company’s stock in a transaction dated Friday, May 29th. The shares were sold at an average price of $160.00, for a total value of $80,000.00. Following the completion of the transaction, the chief accounting officer owned 14,446 shares in the company, valued at approximately $2,311,360. This represents a 3.35% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Scott M. Davies sold 615 shares of the firm’s stock in a transaction that occurred on Thursday, July 30th. The shares were sold at an average price of $200.00, for a total transaction of $123,000.00. Following the completion of the sale, the insider owned 20,338 shares in the company, valued at $4,067,600. The trade was a 2.94% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 1,415,351 shares of company stock worth $255,966,311 in the last 90 days. 2.90% of the stock is currently owned by insiders.

Illumina Stock Up 8.9%

NASDAQ:ILMN opened at $205.00 on Thursday. The company has a current ratio of 1.80, a quick ratio of 1.40 and a debt-to-equity ratio of 0.53. The stock has a 50 day moving average of $185.90 and a 200-day moving average of $151.49. The firm has a market capitalization of $30.95 billion, a PE ratio of 38.25, a price-to-earnings-growth ratio of 2.65 and a beta of 1.45. Illumina, Inc. has a 52 week low of $88.00 and a 52 week high of $207.00.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.23 by $0.08. Illumina had a return on equity of 29.84% and a net margin of 18.36%.The business had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.13 billion. During the same quarter last year, the business posted $1.19 EPS. The business’s revenue was up 9.4% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. Analysts predict that Illumina, Inc. will post 5.36 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have commented on ILMN. Barclays increased their target price on Illumina from $145.00 to $160.00 and gave the stock an “underweight” rating in a report on Friday, July 31st. Stifel Nicolaus upped their price target on Illumina from $155.00 to $225.00 and gave the company a “buy” rating in a research report on Friday, July 31st. Sanford C. Bernstein restated a “market perform” rating and set a $215.00 price objective on shares of Illumina in a research note on Friday, July 31st. Piper Sandler reaffirmed an “overweight” rating and issued a $225.00 price objective (up from $200.00) on shares of Illumina in a report on Monday, August 3rd. Finally, TD Cowen boosted their target price on shares of Illumina from $192.00 to $210.00 and gave the company a “hold” rating in a research note on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, six have issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $188.40.

Illumina Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.